Listen "The Orphaned Drug - How the world came together to treat River Blindness"
Episode Synopsis
In June 2018 the US FDA approved the drug moxidectin for the treatment of River Blindness. How did this drug with no market and no chance of profit get through FDA approval? This podcast is a tale of two cities; two people on opposite sides of the world came together to produce a new drug to treat the disease. Mark Sullivan, Founder & Managing Director of Medicines for Global Health and John Reeder, the Director of the Special Programme for Research and Training in Tropical Diseases tell us how this orphaned drug came to be and how it will contribute to the elimination of River Blindness.
More episodes of the podcast Contain This: The Latest in Global Health Security
From the field: Supporting health outcomes in Vanuatu through DFAT’s Australian Volunteers Program
13/10/2023
The state of gender equality in global health: A deep dive into the 6th Global Health 50/50 report
01/10/2023
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.